Analyst Price Target is $6.33
▲ +231.59% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Unicycive Therapeutics in the last 3 months. The average price target is $6.33, with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 231.59% upside from the last price of $1.91.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Unicycive Therapeutics.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.